A phase I multicenter, open-label study examined the maximum tolerated dose of a Lonsurf and oxaliplatin combination in patients with mCRC.
A safety and tolerability assessment was conducted among elderly patients (age ≥65 years) with mCRC that participated in a Lonsurf expanded access program in the US. The results of the analysis showed that the safety profile and treatment duration of Lonsurf in patients aged 65 and older with mCRC were similar to those in patients aged under 65.
A post-hoc analysis of the pivotal phase 3 RECOURSE study was conducted to assess the correlation between baseline neutrophil-to-lymphocyte ratios in the blood of patients with refractory mCRC treated with Lonsurf and clinical outcomes. Further research is warranted to assess if NLR can be a stratification factor in mCRC clinical trials.
Lonsurf is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated in US for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the US. The company has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents.
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R and D-driven specialty pharma focusing on the fields of oncology, allergy and immunology, and urology. The company is expanding its global R and D efforts and recently established commercial operations in the US.
Servier, governed by a non-profit foundation, has an international presence in 148 countries and employs 21,000 people worldwide. Entirely independent, the group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development in five areas: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancers and diabetes.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary